Seeking Alpha

Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under...

Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news.
Comments (11)
  • Day Trader001
    , contributor
    Comments (675) | Send Message
     
    "Great news for ARNA & VVUS"!!!
    21 Nov 2012, 11:17 AM Reply Like
  • Chemist357
    , contributor
    Comments (184) | Send Message
     
    Sweet!!!

     

    Glad VVUS is making the launch for Belviq that much easier, may even hit the market with 50% insurance coverage!
    21 Nov 2012, 11:51 AM Reply Like
  • Day Trader001
    , contributor
    Comments (675) | Send Message
     
    Excellent point!
    21 Nov 2012, 02:46 PM Reply Like
  • ralphey
    , contributor
    Comments (334) | Send Message
     
    all useless drugs generic plegine most weight loss least cost period
    21 Nov 2012, 11:14 PM Reply Like
  • Chemist357
    , contributor
    Comments (184) | Send Message
     
    When Belviq is in combination with metformin as 1st line therapy for type II diabetic patients....still worthless drug? Open your Cramer closed eyes!
    22 Nov 2012, 12:21 PM Reply Like
  • ralphey
    , contributor
    Comments (334) | Send Message
     
    cHEMIST the answer is yes useless because the weight loss from belviq is absolutely dismal - you can lose more in one month on generic plegine for $20 than an entire year on belviq at a $1000 and generic metformin is a whole lot cheaper as well

     

    not to mention that their are already a number of diabetic drugs that are causing weight loss
    23 Nov 2012, 09:52 AM Reply Like
  • Chemist357
    , contributor
    Comments (184) | Send Message
     
    Wow ralphey,

     

    You must be SHORT on ARNA, when I bought ARNA I did and still do not care about weight loss...What I do care about is diabetic patients who did not lose weight having an A1c reduction of 0.9%. (BLOOM Trial). I suggest you find a health care professional to help you understand the trial data. So you can exit your short position while you still can.

     

    Pharm.D.
    23 Nov 2012, 05:26 PM Reply Like
  • Day Trader001
    , contributor
    Comments (675) | Send Message
     
    @ralp

     

    You are sounding a bit ridiculous!
    23 Nov 2012, 08:14 PM Reply Like
  • ralphey
    , contributor
    Comments (334) | Send Message
     
    Wow a whole 0.9% wow !!! I dont think any diabetic drug has ever done that ! and lets see if i remember weight loss was an average of 5kg at 2 years vs 2 for placebo so lets see 6# weight loss in 2 years on the drug whew impressive !!!

     

    so lets see useless for weight loss and as a diabetic drug mediocre at best wow sound like a real winner
    sorry dont have any investment in this play
    24 Nov 2012, 10:49 AM Reply Like
  • Day Trader001
    , contributor
    Comments (675) | Send Message
     
    You say "sorry don't have any investment in this play"!

     

    Then there is no need your you to be in this conversation, your comments are useless once again!
    24 Nov 2012, 06:45 PM Reply Like
  • ralphey
    , contributor
    Comments (334) | Send Message
     
    Oh I see only people who buy the stock have anything usefull to say DUH !!!!
    25 Nov 2012, 07:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|